Trending menu:
News
-
27 February 2020
Novavax starts animal testing of coronavirus vaccine candidates
US-based biotechnology company Novavax has begun testing its new coronavirus vaccine candidates in animal models. The company constructed several vaccine candidates against Covid-19.
-
27 February 2020
Gilead launches remdesivir’s Phase III trials in Covid-19 patients
Gilead Sciences has commenced two Phase III clinical trials of its investigational antiviral drug, remdesivir, for the treatment of Covid-19 in adults.
-
26 February 2020
UBC, Apeiron Biologics to trial coronavirus drug candidate in China
A researcher at the University of British Columbia in Canada has partnered with Austria-based biotechnology firm Apeiron Biologics to conduct a pilot clinical trial of a new drug candidate to...
-
26 February 2020
Zhittya gets regulatory approval in Mexico for trial of drug in PD patients
Zhittya Genesis Medicine has secured regulatory approval from Mexico's governing body COFEPRIS to test its drug in people with Parkinson's disease (PD).
-
26 February 2020
US begins trial of Gilead’s remdesivir in Covid-19 patients
The National Institutes of Health (NIH) has reported that a clinical trial assessing Gilead Sciences’ remdesivir in hospitalised Covid-19 patients in the US has started.
-
25 February 2020
New legislation gives patients equal access to cancer trials in Illinois
Illinois lawmakers have introduced new legislation called SB1711, the Clinical Trial Participation Act, that gives all cancer patients access to potentially life-saving breakthrough medical treatments in clinical trials.
-
25 February 2020
Moderna delivers coronavirus vaccine candidate for Phase I trial
Moderna has shipped the first vials of its coronavirus vaccine candidate, mRNA-1273, to the Institute of Allergy and Infectious Diseases (NIAID).
-
25 February 2020
NGM Bio’s aldafermin shows favourable profile in Phase II NASH study
NGM Biopharmaceuticals has reported positive data from the fourth cohort of a Phase II clinical trial of aldafermin in non-alcoholic steatohepatitis (NASH) patients.
-
25 February 2020
United Therapeutics’ Tyvaso meets goals in PH-ILD patients
United Therapeutics has reported that the Tyvaso (treprostinil) inhalation solution met all primary and secondary endpoints in the Phase III INCREASE trial involving patients with pulmonary hypertension caused by interstitial...
-
25 February 2020
Bristol-Myers initiates new cohort in Phase I/II trial of BMS-986249
Bristol-Myers Squibb (BMS) has launched an expanded Phase II cohort in the ongoing Phase I/IIa clinical trial of CytomX Therapeutics’ anti-CTLA-4 Probody candidate, BMS-986249.